Press release, Helsinki, 10 January 2024 at 10 AM (EET)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a healthcare services group based in the US. The system will mainly be used in neurosurgery for presurgical mapping of the brain.
Nexstim’s NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for presurgical mapping of the speech and motor cortices of the brain. In addition to its motor and speech mapping features, this specific system also includes therapeutic capabilities that allow the system to be used for the treatment of major depressive disorder (MDD).
Mikko Karvinen, CEO of Nexstim, comments: “We warmly welcome this healthcare services group to our strong user community in the US. Nexstim NBS System 5, using our state-of-the-art navigated transcranial magnetic stimulation (nTMS) technology, is the only FDA cleared and CE-marked nTMS system for pre-operative mapping of the motor and speech cortices of the brain. Nexstim mapping offers you the chance to improve outcomes and your patients’ quality of life.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com